AstraZeneca reports second-quarter profits that exceed analyst expectations while maintaining long-term revenue targets.
AstraZeneca reported second-quarter results on Monday that exceeded profit expectations. The Anglo-Swedish pharmaceutical company maintained its 2026 guidance and its $80 billion annual revenue target for 2030. These results come as the broader market prepares for a major earnings season. Analysts estimate the S&P 500 earnings growth rate for the second quarter will be 23.2%, which is significantly higher than the five-year average of 16.4% and the 10-year average of 10.3%. If these estimates hold, it will mark the second consecutive quarter of earnings growth above 20% for the index and the seventh straight quarter of double-digit growth. The week ahead includes reports from major corporations such as Microsoft, Meta Platforms, and Apple, following a tech sector tailspin triggered by recent results from Alphabet and Tesla.